Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SRT Versus WBRT Combined With Pyrrotinib and Capecitabine in the Treatment of HER2-positive Advanced Breast Cancer Patients With Brain Metastases: A Randomized Controlled, Prospective Clinical Study

NCT05042791 is registered in ClinicalTrials.gov with Jiangxi Provincial Cancer Hospital as lead sponsor.

NCT NCT05042791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05042791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SRT Versus WBRT Combined With Pyrrotinib and Capecitabine in the Treatment of HER2-positive Advanced Breast Cancer Patients With Brain Metastases: A Randomized Controlled, Prospective Clinical Study
Lead sponsor
Jiangxi Provincial Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2022
Completion date
September 30, 2025
Enrollment
362 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive metastatic breast cancer